Phlorizin, a nonselective inhibitor of SGLT1 and SGLT2, reduces BG in preclinical models of T2DM [9] and, due to its insulin-independent mechanism of action, also lowers BG in models of type 1 diabetes [9], [10]. Here, INS is linked to type 2 diabetes mellitus.